Moreover, DNA microarray analysis showed that CXCL13 was the gene on which glucocorticoids exert the most significant effect, suggesting that CXCL13 is a major target of glucocorticoids in MG treatment (95). The gene discussed is CXCL13; the disease is myasthenia gravis.